Compare Redwire Corporation (RDW) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Redwire Corporation vs Vertex Pharmaceuticals Incorporated — how do they compare? Redwire Corporation trades at $8.97 (market cap $2.25B), while Vertex Pharmaceuticals Incorporated trades at $474.2 (market cap $122.33B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 54.4× Redwire Corporation's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Redwire Corporation nearer its low. Which is the better fit depends on your goals.
| RDW | VRTX | |
|---|---|---|
Market Cap | $2.25B | $122.33B |
Sector | Technology | Health |
52-Week High | $25.90 | $529.59 |
52-Week Low | $5.06 | $366.54 |
Enterprise Value | $2.31B | $117.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Redwire (RDW) trades at $8.60, down 1.78% with a bearish technical signal despite oversold RSI readings. The company shows strong revenue growth potential with a record $492 million backlog and a 1.92 book-to-bill ratio, but faces significant profitability challenges with a net income margin of -80.9% and consecutive earnings misses. Recent expansions in Indiana and Alabama highlight operational growth amid substantial cash burn from operations.
The stock presents a high-risk, high-reward opportunity with an 80% analyst buy rating and a $19.00 consensus price target implying over 120% upside. However, persistent losses, negative cash flow from operations, and potential dilution from a $500 million ATM offering pose substantial risks to near-term shareholder value.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
